Acute Kidney Injury Acute Kidney Injury
Conditions
Interventions
The patients will be assigned to one of the following continuous veno-venous hemofiltration filters: Hemofeel CH (CH-1.8W) (PMMA membrane) or Hemofeel SNV (SNV-1.0) (PS membrane).
D000079664
Continuous Renal Replacement Therapy
Sponsors
Kasugai Daisuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients meeting all of the following criteria will be included: 1.Aged 18 years or older. 2.Undergoing the first session of continuous renal replacement therapy (CRRT) after admission to the target ICU. 3.Receiving CRRT as renal replacement therapy (RRT) for acute kidney injury (AKI), based on KDIGO Stage 3 criteria, as follows: (1) Urine output is expected to remain below 0.3 mL/kg/h for more than 24 hours.(2) Serum creatinine has increased to more than three times the baseline level.(3) Serum creatinine is 4 mg/dL or higher and has increased by at least 0.5 mg/dL within 48 hours. Also, the attending physician must determine that the patient is a candidate for continuous renal replacement therapy.
Exclusion criteria
Exclusion criteria: 1. Patients with chronic kidney disease (those undergoing or scheduled to undergo intermittent dialysis). 2. Patients undergoing peritoneal dialysis. 3. When a clinician determines that the use of specific dialysis membranes (such as CH-1.8W, SNV1.0, or a combination with PMX-DHP) is appropriate (i.e., when the clinician deems randomization to be inappropriate). 4. Patients undergoing plasma exchange. 5. Patients undergoing high-flow hemodiafiltration (HDF) or those considered difficult to manage under the standard settings of continuous renal replacement therapy at each facility. 6. Patients with postrenal acute kidney injury. 7. Patients with hemolytic uremic syndrome (HUS). 8. Patients with thrombotic thrombocytopenic purpura (TTP). 9. Patients within 12 months of a kidney transplant. 10. Patients who have already been enrolled in this study once.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Filter lifetime during the first session after allocation | — |
Secondary
| Measure | Time frame |
|---|---|
| Filter lifetime during sessions after the initial session following allocation, 28-day vasopressor-free days, 28-day ventilator-free days, 28-day renal recovery, Major adverse kidney events at 30 days (MAKE30), Major adverse kidney events at 90 days (MAKE90), 90-day renal recovery, 28-day mortality, 90-day mortality, Activities of daily living (ADL) score (EQ-5D-5L) at 6 months after enrollment | — |
Contacts
Public ContactDaisuke Kasugai
Nagoya University Hospital
Outcome results
None listed